Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

One of the highlights of the recent American Association for Cancer Research annual meeting was a plenary session updating the results of the ongoing BATTLE trial at MD Anderson in non-small cell lung cancer (NSCLC).

The more scientific readers will want to check out the academic paper and commentaries published in Cancer Discovery, (see below) or listen to the complimentary AACR webcast of the plenary talk including Dr Hong’s Reverse Migration Strategy, but I realised that not everyone is familiar with, or understands the background, to this ground breaking study.

It therefore seems a great opportunity to use Storify to collate resources and snippets from social media sources to create a story around the events that have happened over the last year…



ResearchBlogging.orgKim, E., Herbst, R., Wistuba, I., Lee, J., Blumenschein, G., Tsao, A., Stewart, D., Hicks, M., Erasmus, J., Gupta, S., Alden, C., Liu, S., Tang, X., Khuri, F., Tran, H., Johnson, B., Heymach, J., Mao, L., Fossella, F., Kies, M., Papadimitrakopoulou, V., Davis, S., Lippman, S., & Hong, W. (2011). The BATTLE Trial: Personalizing Therapy for Lung Cancer Cancer Discovery DOI: 10.1158/2159-8274.CD-10-0010

Sequist, L., Muzikansky, A., & Engelman, J. (2011). A New BATTLE in the Evolving War on Cancer Cancer Discovery DOI: 10.1158/2159-8274.CD-11-0044

Rubin, E., Anderson, K., & Gause, C. (2011). The BATTLE Trial: A Bold Step toward Improving the Efficiency of Biomarker-Based Drug Development Cancer Discovery DOI: 10.1158/2159-8274.CD-11-0036

One Response to “Update on the BATTLE trial in lung cancer”

  1. Anonymous

    Dear  Dr. Waun Ki Hong

    It’s a great pleasure to read your blog. I
    find your post very informative. The goal is
    to assign a patient to the clinical trial that offers the best benefit based on
    the characteristics of his/her tissue biomarker profile; in other words,
    treatment is individualized.

    As a reader, I consider your writing to be a
    great example of a quality and globally competitive output. It would be a great
    thrill and honor if you could share your genuine ideas and knowledge to our
    community, Physician Nexus. With this you can gain 1000 physician readers from
    over 62 countries on Nexus.

    We would love for you to visit our
    community.  It’s free, takes seconds, and
    is designed for physicians only – completely free of industry bias and
    commercial interests.


    Lee Marie Lomoljo

    On behalf of the Physician Nexus Team

Comments are closed.

error: Content is protected !!